Treating Psoriasis as a T-Cell Mediated Disease
Outpatient treatment costs for psoriasis are estimated at $1.6 to $3.2 billion annually. In the commercial managed care population, psoriasis treatment consumes about $7 per member per year (PMPY), including prescription drugs and physician services.
The potential market for new biologic agents is significant. If all patients with moderate to severe disease were treated with a biologic agent, the potential cost would approach $5 billion annually, which translates to $15 PMPY for the entire managed care population.